NO2680834T3 - - Google Patents

Info

Publication number
NO2680834T3
NO2680834T3 NO12710026A NO12710026A NO2680834T3 NO 2680834 T3 NO2680834 T3 NO 2680834T3 NO 12710026 A NO12710026 A NO 12710026A NO 12710026 A NO12710026 A NO 12710026A NO 2680834 T3 NO2680834 T3 NO 2680834T3
Authority
NO
Norway
Application number
NO12710026A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2680834T3 publication Critical patent/NO2680834T3/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
NO12710026A 2011-05-03 2012-03-02 NO2680834T3 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11003603 2011-05-03

Publications (1)

Publication Number Publication Date
NO2680834T3 true NO2680834T3 (pt) 2018-03-17

Family

ID=44652117

Family Applications (1)

Application Number Title Priority Date Filing Date
NO12710026A NO2680834T3 (pt) 2011-05-03 2012-03-02

Country Status (24)

Country Link
US (3) US9446008B2 (pt)
EP (3) EP3766489B1 (pt)
JP (3) JP6027549B2 (pt)
KR (2) KR102039320B1 (pt)
CN (1) CN103501774A (pt)
AU (2) AU2012224954C1 (pt)
BR (1) BR112013022556A8 (pt)
CA (1) CA2828637C (pt)
CY (1) CY1119725T1 (pt)
DK (1) DK2680834T3 (pt)
EA (2) EA025194B1 (pt)
ES (2) ES2910085T3 (pt)
HR (1) HRP20171836T1 (pt)
HU (1) HUE037491T2 (pt)
IL (2) IL227826B (pt)
LT (1) LT2680834T (pt)
MX (1) MX344473B (pt)
NO (1) NO2680834T3 (pt)
PL (1) PL2680834T3 (pt)
PT (2) PT2680834T (pt)
RS (1) RS56692B1 (pt)
SI (1) SI2680834T1 (pt)
WO (1) WO2012119729A1 (pt)
ZA (1) ZA201306480B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3287123T (lt) 2011-03-04 2020-06-10 Grünenthal GmbH Vandeninė farmacinė tapentadolio kompozicija, skirta gerti
PL2680834T3 (pl) 2011-03-04 2018-03-30 Grünenthal GmbH Półstała wodna kompozycja farmaceutyczna zawierająca tapentadol
US9395306B2 (en) 2011-08-05 2016-07-19 Halliburton Energy Services, Inc. Methods for monitoring fluids within or produced from a subterranean formation during acidizing operations using opticoanalytical devices
US8997860B2 (en) 2011-08-05 2015-04-07 Halliburton Energy Services, Inc. Methods for monitoring the formation and transport of a fracturing fluid using opticoanalytical devices
US8619256B1 (en) 2012-09-14 2013-12-31 Halliburton Energy Services, Inc. Systems and methods for monitoring the properties of a fluid cement composition in a flow path
US20140076550A1 (en) 2012-09-14 2014-03-20 Halliburton Energy Services, Inc. Systems and Methods for Detecting Microannulus Formation and Remediation
US9228940B2 (en) 2012-09-14 2016-01-05 Halliburton Energy Services, Inc. Systems, methods, and apparatuses for in situ monitoring of cement fluid compositions and setting processes thereof
EP3027214A1 (en) * 2013-08-02 2016-06-08 ratiopharm GmbH Composition comprising tapentadol in a dissolved form
EP2845625A1 (en) 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
EP3479823B1 (en) 2015-03-27 2020-09-09 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
PE20190908A1 (es) * 2016-09-23 2019-06-26 Gruenenthal Chemie Formulacion estable para la administracion parenteral de tapentadol
US20210290536A1 (en) * 2018-07-24 2021-09-23 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Topical emulsion of an anticholinergic compound

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775678A (en) * 1984-10-01 1988-10-04 Schering Corporation Clotrimazole cream
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6183758B1 (en) * 1998-01-29 2001-02-06 Highland Laboratories, Inc. Phytochemicals, nutrients & medication absorption &/or treatment
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
DE10109763A1 (de) 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
US20050176790A1 (en) 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
EP1485078B1 (en) 2002-03-15 2012-09-26 Cypress Bioscience, Inc. Milnacipran for the treatment of irritable bowel syndrome
US20030191187A1 (en) 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
RU2359698C2 (ru) 2002-09-13 2009-06-27 Сайдекс, Инк. Капсулы, содержащие водные наполняющие композиции, стабилизированные производным циклодекстрина
US20040180915A1 (en) 2003-03-14 2004-09-16 Xanodyne Pharmacal, Inc. Methadone-containing compositions for parenteral administration and method of use thereof
US20060111382A1 (en) 2004-05-17 2006-05-25 Pharmacofore, Inc. Compositions and methods for treating or preventing pain
ES2291780T3 (es) 2004-06-28 2008-03-01 Grunenthal Gmbh Formas cristalinas del clorhidrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)fenol.
CA2572352A1 (en) 2004-07-01 2006-01-12 Gruenenthal Gmbh Oral dosage form safeguarded against abuse containing (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol
AU2006239313A1 (en) 2005-04-28 2006-11-02 Najib Babul Methods and compositions for treating pain
TWI329334B (en) 2005-12-02 2010-08-21 Chung Shan Inst Of Science Manufacture method of electromagnetic interference layer for the plasma display panel
US20080039405A1 (en) * 2006-04-25 2008-02-14 Croda, Inc. Modification of percutaneous absorption of topically active materials
CN101426485B (zh) 2006-04-28 2013-02-13 格吕伦塔尔有限公司 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚和nsaid的药物组合物
AU2007247481B2 (en) 2006-04-28 2013-02-14 Grunenthal Gmbh Pharmaceutical combination comprising 3- ( 3-Dimethylamino-1-ethyl-2-methyl-propyl) -phenol and paracetamol
MX2009000911A (es) 2006-07-24 2009-02-04 Janssen Pharmaceutica Nv Preparacion de (2r,3r)-3-(3-metoxifenil)-n,n,2-trimetilpentanamina .
DE102007012165A1 (de) * 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
EP1985292A1 (en) 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
RS55769B1 (sr) 2007-11-23 2017-07-31 Gruenenthal Gmbh Kompozicije tapentadola
KR101616246B1 (ko) 2008-01-25 2016-05-02 그뤼넨탈 게엠베하 약제학적 투여형
CN104257600A (zh) 2008-10-30 2015-01-07 格吕伦塔尔有限公司 新型有效的他喷他多剂型
WO2010100477A2 (en) 2009-03-03 2010-09-10 Shire Llc Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
US20100272815A1 (en) 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
US20110190267A1 (en) * 2010-01-05 2011-08-04 Shire Pharmaceuticals, Inc. Prodrugs of opioids and uses thereof
AU2011235597B2 (en) * 2010-03-30 2015-07-16 Phosphagenics Limited Transdermal delivery patch
GB201006200D0 (en) 2010-04-14 2010-06-02 Ayanda As Composition
US20120270848A1 (en) * 2010-10-22 2012-10-25 Galleon Pharmaceuticals, Inc. Novel Compositions and Therapeutic Methods Using Same
PL2680834T3 (pl) 2011-03-04 2018-03-30 Grünenthal GmbH Półstała wodna kompozycja farmaceutyczna zawierająca tapentadol

Also Published As

Publication number Publication date
MX2013010100A (es) 2013-10-01
EP2680834A1 (en) 2014-01-08
EA201300988A1 (ru) 2014-06-30
MX344473B (es) 2016-12-16
CY1119725T1 (el) 2018-06-27
AU2012224954C1 (en) 2017-04-06
EA033171B1 (ru) 2019-09-30
SI2680834T1 (en) 2018-01-31
DK2680834T3 (en) 2017-12-04
CA2828637A1 (en) 2012-09-13
EP2680834B1 (en) 2017-10-18
BR112013022556A8 (pt) 2018-01-16
WO2012119729A1 (en) 2012-09-13
JP2018065839A (ja) 2018-04-26
JP2014506900A (ja) 2014-03-20
KR20140013020A (ko) 2014-02-04
PT2680834T (pt) 2018-01-25
JP2017039756A (ja) 2017-02-23
RS56692B1 (sr) 2018-03-30
JP6259042B2 (ja) 2018-01-10
AU2012224954A1 (en) 2013-09-19
PT3766489T (pt) 2022-04-07
US20120225950A1 (en) 2012-09-06
EP3766489A1 (en) 2021-01-20
US9446008B2 (en) 2016-09-20
EA025194B1 (ru) 2016-11-30
ES2654407T3 (es) 2018-02-13
KR101911362B1 (ko) 2018-10-25
IL258357A (en) 2018-05-31
HUE037491T2 (hu) 2018-09-28
IL227826A0 (en) 2013-09-30
HRP20171836T1 (hr) 2017-12-29
AU2017200040A1 (en) 2017-02-02
LT2680834T (lt) 2018-01-10
JP6670283B2 (ja) 2020-03-18
IL227826B (en) 2018-04-30
CA2828637C (en) 2019-06-11
US20160346229A1 (en) 2016-12-01
KR20180116463A (ko) 2018-10-24
ES2910085T3 (es) 2022-05-11
EP3290029B1 (en) 2020-09-02
ZA201306480B (en) 2014-05-28
CN103501774A (zh) 2014-01-08
BR112013022556A2 (pt) 2016-12-06
JP6027549B2 (ja) 2016-11-16
EP3290029A1 (en) 2018-03-07
PL2680834T3 (pl) 2018-03-30
KR102039320B1 (ko) 2019-11-01
EP3766489B1 (en) 2022-03-16
AU2012224954B2 (en) 2016-10-20
AU2017200040B2 (en) 2018-09-06
US20180133174A1 (en) 2018-05-17
EA201600442A1 (ru) 2017-02-28

Similar Documents

Publication Publication Date Title
BR112013022641A2 (pt)
AP3853A (pt)
BR112013031251A2 (pt)
BR112013027245A2 (pt)
BR112013024383A2 (pt)
BR112013026905A2 (pt)
BR112013023185A2 (pt)
BR112013022995A2 (pt)
BR112013026744A2 (pt)
BR112013017670A2 (pt)
BR112013023927A2 (pt)
BR112013027830A2 (pt)
BR112013024365A2 (pt)
BR112013027121A2 (pt)
BR112013027452A2 (pt)
AP2016009466A0 (pt)
BR112013031556A2 (pt)
BR112013026790A2 (pt)
BR112013024588A2 (pt)
BR112013032380A2 (pt)
BR112013032377A2 (pt)
BR112013032366A2 (pt)
BR112013018949A2 (pt)
BR112013026895A2 (pt)
BR112013027761A2 (pt)